Workflow
Millendo Therapeutics (MLND) Investor Presentation - Slideshow

Pipeline Highlights - Millendo Therapeutics is developing Livoletide for Prader-Willi Syndrome (PWS), with topline data expected in early 2Q20[5, 63] - The company is also developing Nevanimibe for classic congenital adrenal hyperplasia (CAH), with topline data from cohort 1 expected in 2H20[5, 63] - MLE-301, a preclinical program for vasomotor symptoms (VMS) associated with menopause, is expected to enter first-in-human trials in 2H20[5, 63] Livoletide for Prader-Willi Syndrome (PWS) - PWS affects approximately 1 in 15,000 births due to a spontaneous genetic defect[12] - A Phase 2a clinical trial showed clinically meaningful decreases in Hyperphagia Questionnaire (HQ) scores with livoletide[18, 19] - In the Phase 2a trial, 65% of livoletide-treated patients showed a ≥ 4-point decrease in HQ score[25] - The pivotal Phase 2b study (ZEPHYR) is fully recruited with 158 patients[33] Nevanimibe for Congenital Adrenal Hyperplasia (CAH) - CAH affects approximately 15,000 to 18,000 people in the U S and ~40,000 in Europe[40] - A Phase 2a study demonstrated activity through reductions in 17-OHP, with 70% of subjects experiencing a decrease of ≥ 50% during at least one treatment period[46] - A Phase 2b clinical trial in CAH is ongoing, with topline results from cohort 1 anticipated in 2H20[5, 53] Financial Position - The company has financial strength, with current cash position expected to support capital needs into 2022[5] - As of December 31, 2019, Millendo had a cash balance of $63.5 million[63]